Effects of the P-Selectin Antagonist Inclacumab on Myocardial Damage After Percutaneous Coronary Intervention for Non-ST-Elevation Myocardial Infarction - SELECT-ACS

Description:

The goal of the trial was to evaluate treatment with the P-selectin antagonist inclacumab compared with placebo among patients undergoing percutaneous coronary intervention (PCI) for non–ST-segment elevation myocardial infarction (NSTEMI).